Higher patient adherence to DMDs reduces MS costs

A board to discuss the Multiple Sclerosis modifying drug Copaxone

Higher patient adherence to DMDs reduces MS costs

Postby MSUK » Wed Nov 30, 2011 1:37 am

Image

Avi Dor, Ph.D., professor in the Department of Health Policy, GW School of Public Health and Health Services, was a co-author of a study, in collaboration with Teva Pharmaceuticals, that found that higher patient adherence to disease modifying therapies, like glatiramer acetate (GA), an immunomodulator drug currently used to treat multiple sclerosis, reduced inpatient costs, outpatient costs, and other medical expenses in a national sample of multiple sclerosis patients.

This research was published in the December issue of the Journal of Medical Economics....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1903
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2105
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Return to Copaxone

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users